Halobetasol/tazarotene

< Halobetasol
Halobetasol/tazarotene
Combination of
Ulobetasol propionateCorticosteroid
TazaroteneRetinoid
Clinical data
Trade namesDuobrii
AHFS/Drugs.comMultum Consumer Information
Routes of
administration		Topical
Legal status
Legal status

Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate (a corticosteroid that reduces inflammation and suppresses the immune system) and 0.045% tazarotene (a retinoid that promotes normal skin cell turnover and has anti-inflammatory effects) in a lotion formulation. It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019 and by Health Canada in June 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.